Fig. 1From: Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLCOS trend of 98 patients observed for 42 months treated with pembrolizumab. At 12 months the percentage of alive patients was 57.9% (95% IC, 48.8-68.6)Back to article page